Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors

British Journal of Pharmacology

Volumn 162, Issue 4, 2011, Pages 785-791

  Mewar, Devesh ^a   Wilson, Anthony G ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

biomarkers; pharmacogenetics; pharmacogenomics; response; rheumatoid arthritis; tumour necrosis factor

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; RHEUMATOID FACTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; GENETIC MARKER; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS, PHARMACOLOGICAL; HUMANS; PHARMACOGENETICS; TUMOR NECROSIS FACTORS;

EID: 79251471130     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01099.x     Document Type: Review

References (48)

1. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. (2007). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66: 921-926.
2. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. (2010). Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 69: 817-821.
3. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T, (2006). Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 54: 3782-3789.
4. Braun J, Baraliakos X, Listing J, Sieper J, (2005). Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52: 2447-2451.
5. Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, et al. (2005). C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 52: 42-48.
6. Coulthard LR, Taylor JC, Eyre S, Robinson JI, Wilson AG, Isaacs JD, et al. (2010). Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis DOI: 10.1136/ard.2010.133249.
7. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, et al. (2010). Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62: 1849-1861.
8. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. (2010). Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69: 522-528.
9. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. (2007). Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66: 893-899.
10. Gaur U, Aggarwal BB, (2003). Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66: 1403-1408.
11. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL, (1996). Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism Criteria. Arthritis Rheum 39: 34-40.
12. di Giovine FS, Nuki G, Duff GW, (1988). Tumour Necrosis factor in synovial exudates. Ann Rheum Dis 47: 768-772.
13. Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, Canete JD, (2004). Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 63: 896.
14. Grewal IS, (2009). Overview of TNF superfamily: a chest full of potential therapeutic targets. Adv Exp Med Biol 647: 1-7.
15. Gudbrandsdottir S, Bliddal H, Petri A, Terslev L, Danneskiold-Samsoe B, Bjornhart B, et al. (2004a). Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. Scand J Rheumatol 33: 385-388.
16. Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, et al. (2004b). TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 22: 118-124.
17. Haraoui B, Cameron L, Ouellet M, White B, (2006). Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 33: 31-36.
18. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH, (2003). Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 62 (Suppl. 2): ii13-ii16.
19. Hyrich KL, Watson KD, Silman AJ, Symmons DP, (2006). Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45: 1558-1565.
20. Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, et al. (2009). The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 60: 3217-3224.
21. Klotz U, Teml A, Schwab M, (2007). Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 46: 645-660.
22. Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, et al. (2008). Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 10: R50.
23. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T, (2007). The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol 36: 411-417.
24. Krzysiek R, Breban M, Ravaud P, Prejean MV, Wijdenes J, Roy C, et al. (2009). Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 61: 569-576.
25. MacEwan DJ, (2002). TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14: 477-492.
26. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. (1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
27. Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD, et al. (2008). Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 17: 3532-3538.
28. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. (2005). Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52: 3279-3289.
29. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. (2006). Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33: 712-721.
30. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, et al. (2006). Independent associations of anti-cyclical citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 8: R128.
31. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. (2008). Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 58: 1248-1257.
32. Morozzi G, Fabbroni M, Bellisai F, Cucini S, Simpatico A, Galeazzi M, (2007). Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol 26: 1335-1338.
33. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A, (2009). Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 348: 36-41.
34. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF, (2008). Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6: 644-653.
35. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. (2009). Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68: 69-74.
36. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, et al. (2010). Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 69: 1315-1320.
37. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. (2009). Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68: 1739-1745.
38. Ravetch JV, Bolland S, (2001). IgG Fc receptors. Annu Rev Immunol 19: 275-290.
39. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. (2007). A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56: 3096-3106.
40. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K, (2001). Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299: 119-129.
41. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. (2002). Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418-426.
42. Scallon B, Cai A, Radewonuk J, Naso M, (2004). Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency. Mol Immunol 41: 73-80.
43. Schiff RI, (1986). Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev Infect Dis 8 (Suppl. 4): S449-S456.
44. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR, (2010). Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59: 49-54.
45. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K, (2007). Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66: 548-550.
46. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, et al. (2009). Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68: 531-535.
47. Wallis RS, Ehlers S, (2005). Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34 (5 Suppl. 1): 34-38.
48. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005). Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351-361.